Stockscreener 앱 받기
23.66
3.98%
-0.98
전일 마감가:
$24.64
열려 있는:
$24.72
하루 거래량:
291.43K
Relative Volume:
0.88
시가총액:
$1.05B
수익:
순이익/손실:
주가수익비율:
-
EPS:
-
순현금흐름:
1주 성능:
-8.15%
1개월 성능:
-31.84%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$23.53
$24.72
1주일 범위
$22.68
$25.93
52주 변동 폭
$22.68
$40.17
Avalyn Pharma Inc Stock (AVLN) Company Profile
명칭
Avalyn Pharma Inc
전화
(206) 707-0340
주소
105 W FIRST ST., BOSTON
Compare AVLN vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVLN
Avalyn Pharma Inc
|
23.66 | 1.05B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Avalyn Pharma Inc Stock (AVLN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-02 | 개시 | Raymond James | Outperform |
| 2026-05-26 | 개시 | Evercore ISI | Outperform |
| 2026-05-26 | 개시 | Guggenheim | Buy |
| 2026-05-26 | 개시 | Jefferies | Buy |
| 2026-05-26 | 개시 | Morgan Stanley | Overweight |
Avalyn Pharma Inc 주식(AVLN)의 최신 뉴스
LB Pharmaceuticals Inc (LBRX) Stock Price & News - Syfe
Neurogene Inc. (NGNE) Stock Price & News - Syfe
Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile - Stock Titan
Avalyn Pharma (AVLN) adds ex-FDA leader to its board - Stock Titan
Avalyn Pharma (NASDAQ:AVLN) Rating Increased to Hold at Wall Street Zen - MarketBeat
Bank of New York Mellon Corp Acquires New Shares in Avalyn Pharma Inc. $AVLN - MarketBeat
Nuvectis Pharma, Inc. (NVCT) Stock Price & News - Syfe
AQST Stock Price, Quote & News - Syfe
Avalyn Pharma presents AP01 lung distribution modeling data By Investing.com - Investing.com Canada
Avalyn Pharma presents AP01 lung distribution modeling data By Investing.com - Investing.com Australia
Avalyn Pharma presents AP01 lung distribution modeling data By Investing.com - Investing.com India
Avalyn Pharma presents AP01 lung distribution modeling data - investing.com
Avalyn Pharma presents AP01 lung distribution modeling data By Investing.com - Investing.com UK
People with lung scarring are willing to travel for trials, Avalyn survey finds - Stock Titan
Morgan Stanley's New York healthcare event will include Avalyn Sept. 14 - Stock Titan
Avalyn Pharma Inc. (NASDAQ:AVLN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
AVLN Options Overview History for Avalyn Pharma Stock - Barchart.com
Braidwell LP Invests $26.38 Million in Avalyn Pharma Inc. $AVLN - MarketBeat
Montanova Capital LLC Takes Position in Avalyn Pharma Inc. $AVLN - MarketBeat
Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026 - Barchart.com
Avalyn will present a model of how an inhaled treatment may spread through the lungs - Stock Titan
AVLN Options Volatility — NASDAQ:AVLN - TradingView
AVLN Options Chain — NASDAQ:AVLN - TradingView
Avalyn Pharma (NASDAQ:AVLN) Sets New 1-Year HighHere's Why - MarketBeat
Avalyn Pharma (NASDAQ:AVLN) Cut to Sell at Wall Street Zen - MarketBeat
Novo Holdings A/S (AVLN) discloses 8.8% beneficial stake in Avalyn Pharma - Stock Titan
Jefferies Maintains Avalyn Pharma(AVLN.US) With Buy Rating, Maintains Target Price $52 - Moomoo
Morgan Stanley Maintains Avalyn Pharma(AVLN.US) With Buy Rating, Raises Target Price to $57 - Moomoo
Avalyn Pharma (NASDAQ:AVLN) Hits New 52-Week High Following Better-Than-Expected Earnings - MarketBeat
AVLN SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Avalyn Pharma Inc. Common Stock (NASDAQ: AVLN) Stock Price, News & Analysis - Kalkine
Avalyn Pharma Inc. Common Stock (NASDAQ: AVLN) Stock Price, News & Analysis - kalkine.ca
Avalyn Pharma Q2 Results: EPS misses estimate by 22.64% - scanx.trade
Avalyn Pharma (NASDAQ:AVLN) Trading Up 8.2% Following Better-Than-Expected Earnings - MarketBeat
Form 8K Avalyn Pharma Inc. For: 12 August By Investing.com - Investing.com Nigeria
Avalyn Pharma Inc. Q2 2026: Net loss $(28.9M), EPS $(0.98) — 10-Q Summary - TradingView
Avalyn Pharma's Q2 Net Loss Widens - Yahoo Finance
Avalyn: Q2 Earnings Snapshot - AOL.com
Avalyn: Q2 Earnings Snapshot - 10TV
AVLN: Completed Phase 2b trial enrollment and secured $413.5M cash runway into 2029 - TradingView
Form 8K Avalyn Pharma Inc. For: 12 August By Investing.com - Investing.com Canada
AVLN: Net loss widened on higher R&D spend; IPO proceeds extend cash runway into 2029 - TradingView
Avalyn Pharma reports Q2 2026 net loss $28.9M; cash $413.5M, runway into 2029 - TradingView
Form 8K Avalyn Pharma Inc. For: 12 August By Investing.com - Investing.com UK
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights - marketscreener.com
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewswire
Avalyn Pharma Inc. (NASDAQ:AVLN) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Avalyn Pharma (AVLN): Norwest Venture Partners discloses 5.1% ownership stake - Stock Titan
Biotech Stocks At 52-Week HighsHALO +20% On Q2 Results, FENC, AVLN, AMLX, CHE - RTTNews
Avalyn Pharma (NASDAQ:AVLN) Reaches New 52-Week HighTime to Buy? - MarketBeat
Avalyn Pharma Inc (AVLN) 재무 분석
Avalyn Pharma Inc (AVLN)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Avalyn Pharma Inc 주식 (AVLN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Carroll Jill | Director |
May 01 '26 |
Buy |
18.00 |
277,778 |
5,000,004 |
2,186,562 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
May 01 '26 |
Buy |
18.00 |
555,555 |
9,999,990 |
2,186,562 |
6.77%
자본화:
|
볼륨(24시간):